Loading...
XSHG
600594
Market cap476mUSD
Dec 05, Last price  
4.25CNY
1D
-1.16%
1Q
-2.07%
Jan 2017
-74.47%
IPO
130.14%
Name

Guizhou Yibai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600594 chart
P/E
P/S
1.55
EPS
Div Yield, %
1.55%
Shrs. gr., 5y
-0.07%
Rev. gr., 5y
-8.34%
Revenues
2.17b
-21.74%
739,373,109717,180,0471,006,318,9651,153,937,5491,307,399,6021,467,465,0051,903,335,2522,252,575,4862,784,900,0203,157,075,0763,302,519,1833,686,822,7763,807,661,7583,882,863,1793,361,025,7453,413,192,8863,346,704,6052,735,262,8382,777,902,3602,174,031,578
Net income
-317m
L
69,417,695092,742,58298,131,064121,807,211195,558,577265,483,488333,268,220429,153,586461,165,002171,142,434373,033,839387,529,7930141,895,198219,892,637243,772,1060103,399,049-317,215,358
CFO
87m
-76.99%
17,383,19295,772,39511,943,485189,259,328103,884,268115,660,561277,826,783288,014,258577,241,280541,581,197573,678,658380,616,139681,776,508214,297,431362,713,743366,657,366934,211,133345,299,144377,609,81286,873,036
Dividend
Jun 07, 20240.066 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.
IPO date
Mar 23, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT